Charité-Universitätsmedizin Berlin is the only German medical faculty with a regular Institute of Gender in Medicine (GiM) and the only German faculty teaching Gender Medicine in the regular curriculum.

It is the greatest university hospital in Germany and one of the largest university hospitals in Europe with a yearly budget over 1.3 billion EUR. About 3700 doctors and scientists work here, do research and teach at top international level. Charité has an international reputation for excellence in training.  It extends over four campuses with large research units and 3213 patient beds. Recognized to be one of the leading medical faculties in Europe, the faculty has more than 250 professors and is distinguished by the highest female participation in faculty in Germany with 50 female professors.

TheInstitute of Gender Medicine (GIM) has been founded in 2003 as a loose centre and has been turned into a regular institute in 2007. Staff members are one full professor, 12 postdocs, 7 assistants, 20 students. Associated members are 14 working groups of Charité, with 22 professors. It has at present more than 200 sqm laboratory rooms and office space.

Director of GiM, Vera Regitz-Zagrosek is founding president of International Society of Gender Medicine, president of the German Society DM. She was head of a gender research training programme (DFG: 2001-2011), is head and coordinator of a DFG research group (2008-2014), partner and coordinator for Berlin in German Cardiovascular Research Centre (DZHK), Coordinator of EU projects: EUGIM, PI and gender coordinator in EU projects, partner GenderBasic, expert in Gendered innovations, organizer of yearly national or international gender conferences since 2004, director of German program “Hör auf dein Herz” (Cardiovascular prevention in women),

V. Regitz-Zagrosek is editor of 2 books of in Gender Medicine with Springer “Sex and Gender Aspects in Clinical Medicine” (2011) and “Sex and Gender Differences in Pharmacology, Handbook of Experimental Pharmacology” (2012). She has published more than 200 research articles, more than 100 related to Gender Medicine and is very present in lay media, in ARTE, Spiegel, and Focus.  The European guidelines „Management of Cardiovascular Diseases in Pregnancy" were compiled under the guidance of Prof. Vera Regitz-Zagrosek.

Maastricht University, the most international university in the Netherlands, stands out for its innovative approach to learning and international outlook. With almost 16,000 students and 4,000 staff, UM offers a wide choice of academic programmes, all of which are designed to bring out the best in its students. Almost 45% of our students and more than 30% of the teaching staff come from abroad. Most of programmes are taught in English and European and international themes are deeply rooted in research and education. That creates an international atmosphere that's attractive to Dutch as well as international students and employees.

CAPHRI (School for Public Health and Primary Care) is the largest of the five schools of the Maastricht UMC+ (consisting of the Faculty of Health, Medicine & Life Sciences (FHML) and the Academic Hospital Maastricht (AzM)). Maastricht UMC+ is well known for its expertise in the prevention of diseases, diagnostic and prognostic research in primary care and public health, the promotion of healthy behaviour, and the redesign of health care services. CAPHRI plays a central role in the MUMC+, being at the forefront of scientific, innovative, applied, ethical and policy-related research in public health and primary care. In total, CAPHRI has 629 staff members, including 50 professors and 305 PhD candidates (142 internal candidates with appointments at CAPHRI, and 163 external candidates).

Department HES (Health Ethics & Society)is offering interdisciplinary teaching and research about health in society through philosophy, ethics, sociology, law, gender research, history and anthropology. HES is located at Faculty of Health, Medicine and Life Sciences and within the research school CAPHRI.

Appointed as associate professor of Gender Medicine at Maastricht University Ineke Klinge has a long track record in coordinating and partnering in EU projects aimed at innovation of biomedical research practices. Since 2001 she coordinated the Gender Impact Assessment study of FP5 (life sciences part), was partner in FP6 projects NuGO, SAFEFOODS and Europrevall, implementing the Gender Action Plans of these consortia, coordinated GenderBasic - elected as FP6 success story -  and most recently was co-chair and Rapporteur of the EU/US Gendered  Innovations Project .

She was also partner in the Erasmus educational project EUGIM that developed master modules of Gender Medicine teaching. In the area of Public Health she was partner in the ENGENDER project. She organized a session on Gender Medicine at the ESOF conference in Torino in 2010 that attracted a lot of media and press attention. A press release on the Gendered Innovations project in NL in Spring 2012 led to many interviews and media reporting on Gender Medicine in NL. Major health funding organizations showed their interest.

In the Cost Action gender STE (2012-2014) she leads the work group on dissemination of Gendered Innovations. She further serves on important committees and editorial boards in the Gender Medicine field.

Founded in 1996, the European Institute of Women’s Health (EIWH) is a non-governmental organisation aiming to promote gender equity in public health, research and social policies across Europe.  In striving to achieve the highest standard of health for all, society’s health policies must recognise that women and men-due to their biological differences, their access to resources and their gender roles-have different needs and are faced with different obstacles and opportunities. This mission requires a gender-sensitive approach.  

The EIWH aims to reduce inequalities in health, in particular due to gender, age and socio-economic status by highlighting that gender/sex is an important determinant of health and our understanding how vulnerability to, onset and progression of specific diseases vary in men and women must be improved.

EIWH has worked on various European projects related to gender, including the DG SANCO co-funded project, Inventory of Good Practices for Promoting Gender Equity in Health (ENGENDER), which included a launch at the European Parliament in Brussels and generation of six policy briefings on gender in research and healthcare, DG Research and DG CONNECT— helping to increase awareness of women’s health issues and promoting synergies with other EU programmes in the fields of health and research. The EIWH is partner of iSAC (Innovative solutions for the Attention of Citizens), a DG Connect co-funded project using Information & Communication Technology (ICT) to disseminate health information to citizens.  

The EIWH advocates for gender-sensitive approach to prevention, biomedical research, treatment and care and to that end has organised roundtables at the European Parliament to highlight health topics—such as smoking prevention.  The EIWH’s awareness and advocacy events, include Roundtables at the European Parliament and policy briefings to reduce the chronic disease burden.

The EIWH is represented on a variety of ethics boards, advisory and steering groups including but not limited to the FP7 funded project EUROmediCAT (Safety of medication use in pregnancy), the Innovative Medicines Initiative (IMI) funded project, Electronic Health Records for Clinical Research (EHR4CR), European Partnership Action Against Cancer, European Public Health Alliance Policy Co-ordination Group, European Patients Forum Policy committee, European Federation of Pharmaceutical Industry and Associations (EFPIA) Patient/Industry think tank, European Innovation Partnership on Active and Healthy Ageing, and Supporting Active Ageing through Immunisations (SAATI).  EIWH is member of the Non-communicable Disease Alliance, partner with European Centre of Prevention and Disease Control (ECDC) on European Antibiotics Awareness Day.  The EIWH sits on the Patient and Consumer Working Party (PCWP) of the European Medicines Agency (EMA). 

Peggy Maguire, Director General of the EIWH, a political scientist has been working at EU level highlighting the need for gender equity.  She has worked with the Commission External Advisory Group on ageing and disability, and WHO expert group on gender mainstreaming. P. Maguire initiated many research projects and publications on behalf of the European Institute of Women's Health, including the development of a cancer information site for women and families.  Her publications include: Women’s Health in Europe-Facts and Figures across the EU; Discrimination Against Women and Young Girls in Health Sector; and Reducing Health Inequalities.   She is currently the President of the European Public Health Alliance.

Hildrun Sundseth, President of the EIWH, is responsible for the Institute’s strategy and advocacy for an equitable and gender-sensitive approach in health policy, research, treatment and care.  She is the author of various EIWH policy papers including women in bio-medical research and clinical trials, and Horizon 2020–Agenda for Women’s Health. Before joining the EIWH, she headed the Brussels Office of the European Cancer Patient Coalition after 20 years’ experience for the political and policy work with the EU institutions as Director of European Government Affairs for one of the world's leading pharmaceutical companies. 

Kristin Semancik, Research and Policy Officer at the EIWH, has extensive experience working in government, academia, industry, research and non-profit sector in health and politics in both the United States and Europe. K. Semancik is currently completing her Ph.D. at Trinity College Dublin, studying the effect of the EU on healthcare systems both qualitatively and quantitatively.  At the EIWH, Kristin has worked in several EU projects, including the ENGENDER project; she was responsible for the drafting of the policy briefings in six policy areas relating to gender and health and generating materials for the project launch.